NCT03000569 - A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 11, 2017

Study Completion Date

September 11, 2017

Conditions

Parkinson Disease

Interventions

DRUG

SAGE-217

DRUG

Levodopa

Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).

DRUG

Antiparkinsonian Agent(s)

Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.

Trial Locations (11)

30331

Sage Investigational Site, Atlanta

32216

Sage Investigational Site, Jacksonville

32789

Sage Investigational Site, Winter Park

32806

Sage Investigational Site, Orlando

33135

Sage Investigational Site, Miami

33143

Sage Investigational Site, Miami

48334

Sage Investigational Site, Farmington Hills

77058

Sage Investigational Site, Houston

84058

Sage Investigational Site, Orem

91402

Sage Investigational Site, Panorama City

08009

Sage Investigational Site, Berlin